Immunotech Laboratories Inc. Announces Clinical Trials Updates For Company's AIDS-HIV "IPF" Medicines

PASADENA, Calif., Feb. 20, 2013 /PRNewswire/ -- Immunotech Laboratories, Inc. (PINKSHEETS: IMMB) Today announced the following updates for the International Clinical Trials of the company's patented AIDS-HIV "IPF" Medicine(s).

Immunotech Founder and President Harry Zhabilov today announced the progress with the project IPF-ITV-1 in the European Union. Mr. Zhabilov stated: "We have negotiated with two of the biggest hospitals in Bulgaria (thus, European Union) to carry our clinical trials of IPF-ITV-1 and ITV-2 as follows:

At the Infectious Disease Hospital, Sofia, with Hospital Director Prof. Cherveniakova we will carry out clinical trials of ITV-1 with 50 patients infected with HIV-AIDS in its most advanced stage.

At the Military Hospital, Sofia, with Hospital Director Prof. General Stoyan Tonev we will carry out clinical trials of ITV-2 with 50 patients ill with chronic hepatitis in its most advanced stage." The clinical trials will be conducted parallel with protease inhibitor.

Mr. Zhabilov further stated: "We believe that in both cases, the results will be very good, because in Bulgaria until this point, we have already applied the experimental labeled "IPF" Medicine with HIV infected volunteers and the outcomes to date have been extremely successful."

Immunotech recently completed negotiations in the Republic of Macedonia with Bionika Pharmaceuticals who agreed to carry out clinical trials of IPF-ITV-3 with 50 patients ill with HCV using the "IPF" labeled Experimental Drug Medicines.

The clinical trials in Bulgaria (Referred to as, EU) are scheduled to begin in March 2013 and end in August 2013, which will give Immunotech, the rights to receive approval for huge applications of the "IPF" Medicines. In this respect, Immunotech has had a series of conversations with Mr. Vladimir Stoichev, the Deputy General Director from Sopharma Bulgaria, and the parties have reached agreement for the signing of a contract between Immunotech Laboratories BG and Sopharma for joint production of IPF-ITV.

Sopharma is a leading pharmaceutical company in the European Union.

RELEVANT ARTICLES & LINKS FOR AIDS-HIV MEDICINES

http://news.yahoo.com/gsk-wins-priority-status-hiv-drug-u-161639474--finance.html

About Immunotech Laboratories
Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases such as HIV, Cancer, Hepatitis and Aids. www.immunotechlab.com

Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.

Company Contact: [email protected]

Investor Relations:
The Nabors Group: 713-875-9200
E-mail: [email protected]
www.facebook.com/Naborsgroup

SOURCE Immunotech Laboratories, Inc.